 Jeffrey Maki
Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Angiography | 38 | 2021 | 235 | 7.780 |
Why?
| | Contrast Media | 45 | 2024 | 391 | 7.660 |
Why?
| | Gadolinium | 22 | 2024 | 77 | 4.920 |
Why?
| | Magnetic Resonance Imaging | 37 | 2024 | 3390 | 3.980 |
Why?
| | Image Enhancement | 23 | 2024 | 163 | 3.920 |
Why?
| | Organometallic Compounds | 13 | 2023 | 107 | 3.390 |
Why?
| | Image Interpretation, Computer-Assisted | 13 | 2024 | 253 | 3.260 |
Why?
| | Meglumine | 10 | 2023 | 14 | 2.350 |
Why?
| | Lymphedema | 4 | 2017 | 23 | 2.050 |
Why?
| | Lymphography | 6 | 2023 | 9 | 2.020 |
Why?
| | Renal Artery Obstruction | 10 | 2009 | 29 | 1.730 |
Why?
| | Imaging, Three-Dimensional | 14 | 2023 | 530 | 1.370 |
Why?
| | Gadolinium DTPA | 9 | 2015 | 50 | 1.270 |
Why?
| | Sensitivity and Specificity | 19 | 2021 | 1834 | 1.210 |
Why?
| | Arteries | 4 | 2016 | 263 | 1.190 |
Why?
| | Ferrosoferric Oxide | 3 | 2017 | 23 | 1.150 |
Why?
| | Algorithms | 10 | 2018 | 1618 | 1.100 |
Why?
| | Liver Cirrhosis | 3 | 2014 | 280 | 1.080 |
Why?
| | Water | 5 | 2022 | 441 | 1.080 |
Why?
| | Models, Cardiovascular | 4 | 2016 | 191 | 1.070 |
Why?
| | Liver Neoplasms | 5 | 2015 | 640 | 1.060 |
Why?
| | Peripheral Vascular Diseases | 5 | 2009 | 102 | 1.060 |
Why?
| | Prostatic Neoplasms | 2 | 2024 | 1016 | 1.040 |
Why?
| | Pulmonary Embolism | 2 | 2019 | 210 | 1.030 |
Why?
| | Renal Artery | 8 | 2021 | 34 | 1.020 |
Why?
| | Lymphatic Vessels | 3 | 2023 | 61 | 0.970 |
Why?
| | Liver | 6 | 2023 | 1838 | 0.930 |
Why?
| | Image Processing, Computer-Assisted | 12 | 2023 | 742 | 0.920 |
Why?
| | Blood Chemical Analysis | 2 | 2016 | 95 | 0.920 |
Why?
| | Artificial Intelligence | 2 | 2024 | 245 | 0.890 |
Why?
| | Reproducibility of Results | 21 | 2024 | 3067 | 0.890 |
Why?
| | Peliosis Hepatis | 1 | 2023 | 2 | 0.840 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2014 | 185 | 0.820 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2015 | 272 | 0.780 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2022 | 51 | 0.780 |
Why?
| | Rest | 1 | 2022 | 120 | 0.760 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 334 | 0.750 |
Why?
| | Lymphatic System | 2 | 2020 | 11 | 0.710 |
Why?
| | Artifacts | 12 | 2019 | 126 | 0.670 |
Why?
| | Blood Flow Velocity | 4 | 2016 | 404 | 0.610 |
Why?
| | Patient-Specific Modeling | 2 | 2016 | 39 | 0.610 |
Why?
| | Humans | 76 | 2024 | 129212 | 0.580 |
Why?
| | Venous Thrombosis | 1 | 2019 | 175 | 0.540 |
Why?
| | Middle Aged | 33 | 2019 | 31075 | 0.510 |
Why?
| | Blood Vessels | 2 | 2016 | 187 | 0.490 |
Why?
| | Computer Simulation | 9 | 2017 | 941 | 0.480 |
Why?
| | Software | 2 | 2024 | 607 | 0.470 |
Why?
| | Heterocyclic Compounds | 3 | 2023 | 18 | 0.470 |
Why?
| | Magnetics | 2 | 2016 | 44 | 0.450 |
Why?
| | Lymph Node Excision | 1 | 2015 | 164 | 0.440 |
Why?
| | Radiology Information Systems | 1 | 2014 | 30 | 0.440 |
Why?
| | Male | 39 | 2024 | 63491 | 0.430 |
Why?
| | Medical Records Systems, Computerized | 1 | 2014 | 93 | 0.430 |
Why?
| | User-Computer Interface | 1 | 2014 | 148 | 0.420 |
Why?
| | Phantoms, Imaging | 7 | 2018 | 137 | 0.410 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 96 | 0.400 |
Why?
| | Lymph Nodes | 1 | 2015 | 469 | 0.390 |
Why?
| | Documentation | 1 | 2014 | 183 | 0.390 |
Why?
| | Elasticity Imaging Techniques | 1 | 2012 | 47 | 0.380 |
Why?
| | Blood Proteins | 1 | 2013 | 242 | 0.380 |
Why?
| | Hemangiosarcoma | 1 | 2012 | 20 | 0.380 |
Why?
| | Aneurysm, False | 1 | 2012 | 47 | 0.370 |
Why?
| | Heart Neoplasms | 1 | 2012 | 50 | 0.370 |
Why?
| | Oxygen | 1 | 2016 | 911 | 0.370 |
Why?
| | Osteitis Deformans | 1 | 2010 | 4 | 0.350 |
Why?
| | Coronary Sinus | 1 | 2010 | 7 | 0.350 |
Why?
| | Heart | 1 | 2014 | 637 | 0.340 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2010 | 10 | 0.340 |
Why?
| | Cell Membrane | 1 | 2013 | 730 | 0.330 |
Why?
| | Aged | 23 | 2017 | 22030 | 0.330 |
Why?
| | Coronary Vessels | 1 | 2012 | 240 | 0.330 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2010 | 52 | 0.330 |
Why?
| | Skull | 1 | 2010 | 129 | 0.320 |
Why?
| | Adult | 24 | 2019 | 35464 | 0.320 |
Why?
| | Transducers | 1 | 2009 | 26 | 0.310 |
Why?
| | Restraint, Physical | 1 | 2009 | 68 | 0.310 |
Why?
| | Prospective Studies | 10 | 2023 | 7103 | 0.310 |
Why?
| | Veins | 2 | 2006 | 60 | 0.310 |
Why?
| | Abdomen | 3 | 1998 | 118 | 0.310 |
Why?
| | Female | 34 | 2019 | 68600 | 0.300 |
Why?
| | Aorta | 2 | 2023 | 411 | 0.290 |
Why?
| | Microcirculation | 4 | 1991 | 145 | 0.280 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 262 | 0.280 |
Why?
| | Hematocrit | 1 | 2006 | 93 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 2003 | 0.250 |
Why?
| | Radiology | 1 | 2007 | 161 | 0.240 |
Why?
| | Respiration | 3 | 2007 | 191 | 0.240 |
Why?
| | Predictive Value of Tests | 5 | 2017 | 1944 | 0.230 |
Why?
| | Aortic Valve Insufficiency | 2 | 2017 | 46 | 0.230 |
Why?
| | Mitral Valve Insufficiency | 2 | 2017 | 67 | 0.230 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 87 | 0.210 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 2 | 2015 | 8 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 5 | 2018 | 2525 | 0.200 |
Why?
| | Activation, Metabolic | 1 | 2022 | 4 | 0.200 |
Why?
| | Prostate | 1 | 2024 | 180 | 0.200 |
Why?
| | Injections, Intravenous | 3 | 2019 | 201 | 0.200 |
Why?
| | Carotid Arteries | 2 | 2007 | 196 | 0.190 |
Why?
| | Constriction, Pathologic | 2 | 2021 | 228 | 0.190 |
Why?
| | Observer Variation | 4 | 2018 | 314 | 0.190 |
Why?
| | Thorax | 2 | 2019 | 41 | 0.190 |
Why?
| | ROC Curve | 3 | 2014 | 503 | 0.190 |
Why?
| | Feasibility Studies | 4 | 2019 | 864 | 0.190 |
Why?
| | Echocardiography | 2 | 2017 | 626 | 0.180 |
Why?
| | Angiography, Digital Subtraction | 4 | 2021 | 43 | 0.180 |
Why?
| | Swine | 1 | 2023 | 757 | 0.180 |
Why?
| | Benchmarking | 1 | 2021 | 175 | 0.170 |
Why?
| | Phlebography | 2 | 2019 | 38 | 0.170 |
Why?
| | Motion | 3 | 2009 | 98 | 0.160 |
Why?
| | Monte Carlo Method | 2 | 2017 | 142 | 0.160 |
Why?
| | Brain Mapping | 1 | 2022 | 572 | 0.150 |
Why?
| | Radiation Exposure | 1 | 2019 | 45 | 0.150 |
Why?
| | Pelvis | 1 | 2019 | 103 | 0.150 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 20 | 0.140 |
Why?
| | Models, Statistical | 2 | 2015 | 622 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 115 | 0.140 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 99 | 0.140 |
Why?
| | Glucose | 1 | 2022 | 1000 | 0.140 |
Why?
| | Aged, 80 and over | 6 | 2008 | 7061 | 0.130 |
Why?
| | Total Quality Management | 1 | 2017 | 60 | 0.130 |
Why?
| | Radiation Dosage | 2 | 2018 | 153 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2016 | 41 | 0.130 |
Why?
| | Injections, Intra-Arterial | 1 | 2016 | 25 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1493 | 0.130 |
Why?
| | Surface-Active Agents | 1 | 2017 | 84 | 0.130 |
Why?
| | Arteriovenous Malformations | 1 | 2016 | 26 | 0.130 |
Why?
| | Printing, Three-Dimensional | 1 | 2016 | 86 | 0.130 |
Why?
| | Extremities | 1 | 2016 | 127 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 285 | 0.120 |
Why?
| | Diffusion | 4 | 1991 | 117 | 0.120 |
Why?
| | Prenatal Diagnosis | 1 | 2017 | 190 | 0.120 |
Why?
| | Blood | 1 | 2015 | 103 | 0.120 |
Why?
| | Sarcoidosis | 1 | 2017 | 155 | 0.120 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 543 | 0.120 |
Why?
| | Single-Blind Method | 1 | 2015 | 271 | 0.110 |
Why?
| | Plasma | 1 | 2016 | 206 | 0.110 |
Why?
| | Software Validation | 1 | 2014 | 9 | 0.110 |
Why?
| | Microcomputers | 1 | 2014 | 16 | 0.110 |
Why?
| | Software Design | 1 | 2014 | 23 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2016 | 1424 | 0.110 |
Why?
| | Surgery, Computer-Assisted | 1 | 2015 | 76 | 0.110 |
Why?
| | Radiography | 2 | 2014 | 798 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1092 | 0.110 |
Why?
| | Magnetic Fields | 1 | 2013 | 22 | 0.110 |
Why?
| | Transposition of Great Vessels | 1 | 2014 | 34 | 0.110 |
Why?
| | Electric Impedance | 1 | 2013 | 101 | 0.110 |
Why?
| | Protons | 1 | 2013 | 80 | 0.110 |
Why?
| | Information Storage and Retrieval | 1 | 2014 | 108 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2017 | 336 | 0.100 |
Why?
| | Drug Design | 1 | 2014 | 156 | 0.100 |
Why?
| | Cerebrovascular Circulation | 2 | 1991 | 223 | 0.100 |
Why?
| | Kidney | 2 | 2012 | 1375 | 0.100 |
Why?
| | Angiography | 3 | 2004 | 195 | 0.100 |
Why?
| | Pulmonary Artery | 1 | 2018 | 1096 | 0.100 |
Why?
| | Echocardiography, Doppler | 1 | 2012 | 108 | 0.100 |
Why?
| | Elastic Modulus | 1 | 2012 | 123 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2012 | 161 | 0.090 |
Why?
| | Animals | 8 | 2023 | 35219 | 0.090 |
Why?
| | Leg | 2 | 2004 | 237 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2736 | 0.090 |
Why?
| | Cerebral Infarction | 1 | 1991 | 42 | 0.090 |
Why?
| | Cardiac Valve Annuloplasty | 1 | 2010 | 2 | 0.090 |
Why?
| | Prognosis | 2 | 2016 | 3791 | 0.090 |
Why?
| | Time Factors | 5 | 2017 | 6549 | 0.090 |
Why?
| | Tricuspid Valve | 1 | 2010 | 27 | 0.090 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2010 | 24 | 0.090 |
Why?
| | Carbon Dioxide | 2 | 1991 | 258 | 0.090 |
Why?
| | Equipment Design | 2 | 2009 | 513 | 0.080 |
Why?
| | Pericardium | 1 | 2010 | 54 | 0.080 |
Why?
| | Fourier Analysis | 3 | 2007 | 39 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2010 | 71 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2017 | 3372 | 0.080 |
Why?
| | Adolescent | 5 | 2023 | 20371 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 525 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 547 | 0.080 |
Why?
| | Hypertension, Renal | 1 | 2009 | 16 | 0.080 |
Why?
| | Ventricular Function, Left | 1 | 2012 | 526 | 0.080 |
Why?
| | Spin Labels | 1 | 2009 | 47 | 0.080 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 131 | 0.080 |
Why?
| | Young Adult | 3 | 2016 | 12396 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 383 | 0.070 |
Why?
| | Scattering, Radiation | 1 | 2007 | 100 | 0.070 |
Why?
| | Models, Structural | 3 | 1991 | 39 | 0.070 |
Why?
| | Heart Valve Diseases | 1 | 2009 | 151 | 0.070 |
Why?
| | Pentetic Acid | 2 | 1997 | 13 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 1998 | 398 | 0.070 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 68 | 0.060 |
Why?
| | Electrocardiography | 1 | 2009 | 606 | 0.060 |
Why?
| | Brain | 4 | 1991 | 2664 | 0.060 |
Why?
| | Drug Combinations | 2 | 1997 | 327 | 0.060 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2006 | 84 | 0.060 |
Why?
| | Arterial Occlusive Diseases | 1 | 2004 | 80 | 0.060 |
Why?
| | Vascular Diseases | 1 | 2007 | 241 | 0.060 |
Why?
| | Lung | 1 | 2017 | 3916 | 0.050 |
Why?
| | Indocyanine Green | 1 | 2023 | 19 | 0.050 |
Why?
| | Metacarpophalangeal Joint | 1 | 2023 | 13 | 0.050 |
Why?
| | Atherosclerosis | 1 | 2007 | 402 | 0.050 |
Why?
| | Tomography, Spiral Computed | 1 | 2002 | 27 | 0.050 |
Why?
| | Hepatic Artery | 1 | 2002 | 58 | 0.050 |
Why?
| | Thrombosis | 1 | 2006 | 343 | 0.050 |
Why?
| | Hypertension, Renovascular | 3 | 2009 | 13 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2017 | 14488 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 350 | 0.050 |
Why?
| | Hand | 1 | 2023 | 153 | 0.050 |
Why?
| | Rats | 5 | 1991 | 5462 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1584 | 0.040 |
Why?
| | Neck | 1 | 1998 | 92 | 0.040 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 368 | 0.030 |
Why?
| | Head | 1 | 1998 | 96 | 0.030 |
Why?
| | Ultrasonography | 2 | 2014 | 713 | 0.030 |
Why?
| | Fetal Organ Maturity | 1 | 2017 | 27 | 0.030 |
Why?
| | Heart Failure | 1 | 2010 | 2147 | 0.030 |
Why?
| | Forms and Records Control | 1 | 2017 | 22 | 0.030 |
Why?
| | United States | 1 | 2014 | 13873 | 0.030 |
Why?
| | Technology Assessment, Biomedical | 1 | 2016 | 29 | 0.030 |
Why?
| | Rheology | 2 | 2002 | 90 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1997 | 47 | 0.030 |
Why?
| | Safety | 1 | 1998 | 330 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 133 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2010 | 10189 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4886 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 567 | 0.030 |
Why?
| | Linear Models | 2 | 2002 | 818 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 61 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 152 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2002 | 831 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 235 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2017 | 538 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 857 | 0.030 |
Why?
| | Gestational Age | 1 | 2017 | 872 | 0.030 |
Why?
| | Carotid Artery Diseases | 1 | 2013 | 64 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 2013 | 90 | 0.030 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.030 |
Why?
| | Fetus | 1 | 2017 | 772 | 0.020 |
Why?
| | Body Water | 1 | 1991 | 18 | 0.020 |
Why?
| | Acetone | 1 | 1991 | 12 | 0.020 |
Why?
| | Edetic Acid | 1 | 1991 | 46 | 0.020 |
Why?
| | Lasers | 1 | 1991 | 132 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1713 | 0.020 |
Why?
| | Gels | 1 | 1991 | 82 | 0.020 |
Why?
| | Dextrans | 1 | 1991 | 82 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 1991 | 257 | 0.020 |
Why?
| | Muscles | 1 | 1991 | 322 | 0.020 |
Why?
| | Child | 1 | 2010 | 20853 | 0.020 |
Why?
| | Corpus Striatum | 1 | 1991 | 159 | 0.020 |
Why?
| | Stroke Volume | 1 | 2012 | 590 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1991 | 1083 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 1991 | 432 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2012 | 707 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2007 | 20 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3234 | 0.020 |
Why?
| | Carotid Stenosis | 1 | 2007 | 84 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 27 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1019 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2006 | 254 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 6384 | 0.010 |
Why?
| | Reference Standards | 1 | 2004 | 177 | 0.010 |
Why?
| | Models, Biological | 1 | 1991 | 1718 | 0.010 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2002 | 16 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 421 | 0.010 |
Why?
| | Portal Vein | 1 | 2002 | 108 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 9747 | 0.010 |
Why?
| | Movement | 1 | 2002 | 269 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 2002 | 461 | 0.010 |
Why?
| | Liver Diseases | 1 | 2002 | 288 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2006 | 895 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2002 | 543 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 162 | 0.010 |
Why?
| | Reference Values | 1 | 1997 | 793 | 0.010 |
Why?
| | Body Temperature | 1 | 1991 | 212 | 0.010 |
Why?
| | Death | 1 | 1991 | 121 | 0.010 |
Why?
| | Cell Death | 1 | 1991 | 354 | 0.010 |
Why?
|
|
Maki's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|